These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

732 related items for PubMed ID: 19262226

  • 41. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
    Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Lyle PA, Nieminen MS.
    J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    JAMA; 2004 Nov 17; 292(19):2343-9. PubMed ID: 15547161
    [Abstract] [Full Text] [Related]

  • 46. In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
    Okin PM, Hille DA, Wiik BP, Kjeldsen SE, Lindholm LH, Dahlöf B, Devereux RB.
    Diabet Med; 2013 Oct 17; 30(10):1189-97. PubMed ID: 23587029
    [Abstract] [Full Text] [Related]

  • 47. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
    Fyhrquist F, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H, LIFE Study Group.
    Hypertension; 2005 Apr 17; 45(4):580-5. PubMed ID: 15790960
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
    Kizer JR, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB.
    Hypertension; 2005 Jan 17; 45(1):46-52. PubMed ID: 15583076
    [Abstract] [Full Text] [Related]

  • 51. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
    Okin PM, Hille DA, Kjeldsen SE, Lindholm LH, Edelman JM, Dahlöf B, Devereux RB.
    Am J Hypertens; 2010 Jul 17; 23(7):786-93. PubMed ID: 20395941
    [Abstract] [Full Text] [Related]

  • 52. Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
    Greve AM, Olsen MH, Bella JN, Lønnebakken MT, Gerdts E, Okin PM, Palmieri V, Boman K, Nieminen MS, Omvik P, Dahlöf B, Devereux RB, Wachtell K.
    Am J Hypertens; 2012 Sep 17; 25(9):1017-23. PubMed ID: 22695506
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
    Okin PM, Hille DA, Wachtell K, Kjeldsen SE, Julius S, Devereux RB.
    Blood Press; 2020 Oct 17; 29(5):319-326. PubMed ID: 32586143
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
    Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H, LIFE (Losartan Intervention for Endpoint Reduction) Study Group.
    JAMA; 2002 Sep 25; 288(12):1491-8. PubMed ID: 12243636
    [Abstract] [Full Text] [Related]

  • 60. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
    Díez J.
    Clin Ther; 2006 Jun 25; 28(6):832-48. PubMed ID: 16860167
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.